Lydia J. Eccersley
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Exposure-response analyses for belantamab mafodotin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma from DREAMM-6 Arm B and DREAMM-7.
Journal: British journal of cancer
Published: September 19, 2025
Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trial.
Journal: International journal of hematology
Published: August 19, 2025
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Journal: The Lancet. Oncology
Published: April 28, 2025
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.
Journal: The Lancet. Haematology
Published: January 16, 2025
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Journal: The New England journal of medicine
Published: June 03, 2024
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma.
Journal: Haematologica
Published: June 28, 2022
Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: December 05, 2021
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Journal: British journal of haematology
Published: December 24, 2020
Reduced intensity allogeneic hematopoietic stem cell transplantation is a safe and effective treatment option in high-risk myeloma patients - a single centre experience.
Journal: British journal of haematology
Published: November 08, 2020
Current views of haemolytic streptococcal pathogenesis.
Journal: Current opinion in infectious diseases
Published: February 28, 2014
Showing 1-11 of 11
Last Updated: 09/26/2026